The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
- PMID: 36479863
- PMCID: PMC9752270
- DOI: 10.1002/ueg2.12350
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Abstract
Inflammatory bowel disease (IBD), which comprises Crohn's disease and ulcerative colitis, is an idiopathic inflammatory condition of the gastrointestinal tract. The incidence and prevalence of IBD are rapidly increasing worldwide, particularly in newly industrialized regions such as Asia. Although a large medical armamentarium is available for treating this chronic disease, IBD imposes a marked global disease burden. To understand the complex etiopathogenesis of this condition, it is important to consider the rapidly changing trends in its epidemiology in Asia. During the past few decades, the incidence and prevalence of IBD have significantly increased in both Asian countries and Asian immigrants in Western countries. In this review, we aimed to study and update the epidemiology of IBD in diverse Asian regions and among Asian immigrants in North America and Europe. Moreover, we highlighted that this population exhibits a unique disease phenotype, such as male predominance and high frequency of perianal fistula in Crohn's disease. Also, a different disease phenotype including more complicated disease such as perianal complications was noted in Asian Americans and Asian Europeans.
Keywords: Asia; epidemiology; immigrants; inflammatory bowel disease.
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Conflict of interest statement
Edward V. Loftus has consulted for AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol‐Myers Squibb, CALIBR, Celgene, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharma, Surrozen, Takeda, and UCB; and has received research support from AbbVie, Bristol‐Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Robarts Clinical Trials, Takeda, Theravance, and UCB.
References
-
- East Asia population 2022 12 [cited 2022 May 15]. https://www.worldometers.info/world‐population/eastern‐asia‐population/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous